atbody
An innovative solution for hematological malignancies and auto-immune disease.
antibody payload
technology
for cancer and
auto-immune disease
atbody – our
game-changing
biologic
atbiofarm –
our innovative
technology
We are committed to providing novel therapeutic solutions for
patients with cancer and auto-immune disease.
The atbody has been designed to become a game-changer
format in the antibody-based targeted therapies.
Key value drivers
atbiofarm
Our disruptive and versatile plant-based manufacturing technology.
Discovery
portfolio
Leveraging our unique platform to expand our pipeline in solid tumors.
Our vision
We are creating a new line of
attack against cancer and
autoimmune disease.
Our game-changer atbody format will be a new paradigm in targeted antibody
therapy, addressing unmet clinical needs in multiple therapeutic areas.
Latest press releases
calendar_today 19 May 2026
Encretin Therapeutics Appoints Mark Throsby as CEO to Lead Next Phase of Growth
calendar_today 10 June 2025
Encretin Therapeutics Announces Appointment of Dr. Torsten Dreier as Chief Development Officer and Opening of New R&D Hub in Gent
calendar_today 18 November 2024
In October 2024 Encretin Therapeutics Raises €54 Million Series A Financing
A pioneering biotechnology company dedicated to novel antibody therapies for oncology and auto-immune disease.
social
SOCIAL
